The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …

More about screening … current and future issues

So there are two new articles recently published on the prostate cancer screening issue. One deals with the numbers of men  in America who seem to be getting screened today. The other addresses whether there should be different guidance on prostate cancer screening for African Americans as opposed to “the rest of us” (Caucasians, Hispanics, and “white” Americans). … READ MORE …

Videos from the 2017 APCCC in St. Gallen, Switzerland

The Advanced Prostate Cancer Consensus Conference was held in St. Gallen, Switzerland, on March 9 to 11, and there are a series of video interviews about some of the presentations now available on the UroToday web site … READ MORE …

Another research team, and another micro-RNA …

Last week we mentioned that one specific form of micro-ribonucleic acid (miRNA) may be usable in the development of a drug or drugs to stop the process of metastasis in men with high-risk forms of prostate cancer. Another recent study goes one step further than that. … READ MORE …

A better way to grow prostate cancer cells in the lab

In a very interesting research development, a group at Georgetown University here in the US has finally found a way to be able to extract and grow the normal and cancerous prostate cells from individual patients in the laboratory and then implant them into mice. … READ MORE …

Of moonshots, precision medicine, and progress in the management of cancer

As your sitemaster, let me be very clear about a couple of my most basic beliefs about prostate cancer and prostate cancer research. I want to do this because of all the recent media discussion about Vice President Byden’s “Moonshot” and the possible wonders of precision medicine. … READ MORE …

Action needed to support prostate cancer research funding (again)

Prostate Cancer International and PCPC3 (along with ZERO and others) encourage our American readers to call or e-mail your senators between now and Monday, please … READ MORE …

International prostate cancer registry initiated in Australasia

According to a newly published article in BJU International, a new prostate cancer registry (Prostate Cancer Outcomes Registry — Australia and New Zealand or PCOR-ANZ) has been established to monitor outcomes of prostate cancer treatment and care “in a cost-effective manner”. … READ MORE …

Prostate cancer research funding in the US budget for FY16

The “New” Prostate Cancer InfoLink is pleased to note that, in the final draft of the Omnibus reconciliation bill designed to fund the US federal government from October 1, 2015 through September 31, 2016 (the FY16 budget) there are two important pieces of news for the prostate cancer community. … READ MORE …

Something you can do NOW about the cost of care and “financial toxicities”

In an article in the October 25 issue of The ASCO Post, Dr. Jonas de Souza of the University of Chicago has introduced a new initiative to help all cancer patients and their doctors address the increasing problems associated with the costs of cancer care. … READ MORE …

USPSTF to re-assess harms and benefits of PSA-based screening for risk of prostate cancer

Yesterday the U.S. Preventive Services Task Force (USPSTF) posted detailed information about a new draft research plan related to screening for prostate cancer. … READ MORE …

Survey about use of online support networks for prostate cancer patients

Researchers at George Mason University (GMU) in Fairfax, Virginia, USA are conducting a study to learn more about men’s use and perceptions of online prostate cancer support networks as well as men’s experiences with prostate cancer. We encourage readers to participate in this survey. … READ MORE …

What IS an “N-of-1” clinical trial?

As we come, slowly, closer and closer to truly individualized forms of medical practice, in which individual patients get treated individually based not just on “what works” for most men with (say) prostate cancer that has just progressed to the metastatic stage, clinical researchers are increasingly interested in so-called “N-of-1″ clinical trials. … READ MORE …

Progress in the underlying science of prostate cancer management

Patients (and others) who are interested in an overview of the possible future of development of new agents for the treatment of advanced forms of prostate cancer may want to … READ MORE …

Participate in research survey on cancer and quality of life

Dr. Michael Hoerger and study research assistants at Tulane University are seeking cancer patients willing to complete a brief online survey related to cancer care and quality of life. … READ MORE …